Table 1 Patients’ characteristics at recurrence
Patients n = 17 | n (%) |
|---|---|
Characteristics | |
Gender | |
Male | 10 (59%) |
Female | 7 (41%) |
Median age, years (range) | 50 (26-66) |
Karnofsky performance status | |
Median (range) | 80 (60-100) |
90-100 | 4 (24) |
70-80 | 12 (71) |
60 | 1 (5) |
Laterality | |
Right | 5 (29) |
Left | 12 (71) |
Lobe | |
Fronto-temporal | 5 (29) |
Parieto-temporal | 3 (18) |
Frontal | 2 (12) |
Temporal | 4 (24) |
Parietal | 1 (5) |
Multilobar | 2 (12) |
Histotype | |
Glioblastoma multiforme | 12 (71) |
Grade III gliomas | 5 (29) |
MGMT promoter methylation status at diagnosis | |
Methylated | 9 (53) |
Unmethylated | 3 (18) |
Unknown | 5 (29) |
IDH1 status at diagnosis: | |
Mutated | 5 (29) |
Non mutated | 3 (18) |
Unknown | 9 (53) |
Surgery at recurrence | |
Yes | 15 (88) |
No | 2 (12) |
Chemotherapy treatment | |
First-line therapy | |
STUPP (RT/TMZ-TMZ) | 17 (100%) |
Line of BEV treatment | |
Second | 4 (24) |
Third | 13 (76) |
BEV treatment | |
Monotherapy | 13 (76) |
Combined with FTM | 4 (24) |
Median cycles received, number (range) | 8 (2-40) |